Status:

RECRUITING

Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer

Lead Sponsor:

Geneplus-Beijing Co. Ltd.

Collaborating Sponsors:

Chinese Academy of Medical Sciences

Conditions:

Breast Cancer Screening

Eligibility:

All Genders

30-75 years

Brief Summary

The purpose of this study is to construct an auxiliary diagnostic model for breast cancer by methylation markers. The study will collect blood and tissue samples from participants with breast cancer a...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for All the Participants:
  • With confirmed pathological diagnosis and molecular subtyping results
  • Ability to provide a written informed consent
  • Exclusion Criteria for Cancer Arm Participants:
  • Patients with a history of or currently suffering from other malignancies
  • Pregnant or planning to become pregnant female patients
  • Patients who have received cancer treatment, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, before blood draw
  • Patients with a history of blood transfusion within the past month
  • Patients with a known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
  • Patients with persistent fever or undergoing anti-inflammatory treatment within 14 days before blood draw
  • Any other conditions that the researcher deems may make the patient unsuitable for inclusion in the study or may interfere with the completion of the study
  • Patients in poor physical condition who are not suitable for blood draw
  • Patients who cannot provide informed consent or refuse blood draw
  • Exclusion Criteria for Benign Diseases Arm Participants:
  • History of malignancies
  • Current malignancies or precancerous lesions

Exclusion

    Key Trial Info

    Start Date :

    March 15 2025

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    August 31 2026

    Estimated Enrollment :

    200 Patients enrolled

    Trial Details

    Trial ID

    NCT06876610

    Start Date

    March 15 2025

    End Date

    August 31 2026

    Last Update

    March 14 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China, 100021